85. Idiopathic interstitial pneumonia
514 clinical trials,   377 drugs   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2014-004058-32-GB (EUCTR) | 19/12/2014 | 12/06/2015 | Treating pulmonary fibrosis with co-trimoxazole | The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC) - Treating pulmonary fibrosis with co-trimoxazole | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Cotrimoxazole Product Name: Cotrimoxazole Product Code: NA INN or Proposed INN: trimethoprim Other descriptive name: none INN or Proposed INN: sulphamethoxazole Other descriptive name: none | Norfolk and Norwich University Hospital NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 3 | United Kingdom | ||
2 | NCT01777737 (ClinicalTrials.gov) | November 25, 2013 | 25/1/2013 | Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole | Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Cotrimoxazole;Drug: Placebo | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Junta de Andalucia | Terminated | 18 Years | 80 Years | All | 3 | Phase 3 | Spain |
3 | EUCTR2012-005409-38-ES (EUCTR) | 19/04/2013 | 29/01/2013 | First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole. | Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis | Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis. MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Parasitic Diseases [C03] | Trade Name: SEPTRIN INN or Proposed INN: TRIMETHOPRIM Other descriptive name: TRIMETHOPRIM INN or Proposed INN: SULFAMETHOXAZOLE | Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | NULL | Not Recruiting | Female: yes Male: yes | 56 | Phase 3 | Spain |